|
|
| (95 intermediate revisions by 5 users not shown) |
| Line 1: |
Line 1: |
| − | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''
| + | <span id="BackToTop"></span> |
| − | | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> |
| − | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].
| + | [[#top|Back to Top]] |
| − | | + | </div> |
| | + | {{#lst:Editorial board transclusions|sarcoma}} |
| | {| class="wikitable" style="float:right; margin-right: 5px;" | | {| class="wikitable" style="float:right; margin-right: 5px;" |
| | |- | | |- |
| − | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
| − | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
| | |} | | |} |
| | + | '''Note: this page does not contain any regimens. The following links will take you to disease-specific pages with regimens:''' |
| | + | *<big>Regimens for [[Angiosarcoma|'''Angiosarcoma''' are here]]</big>. |
| | + | *<big>Regimens for [[Kaposi sarcoma|'''Kaposi sarcoma''' are here]]</big>. |
| | {{TOC limit|limit=3}} | | {{TOC limit|limit=3}} |
| − |
| |
| | =Guidelines= | | =Guidelines= |
| − | ==[http://www.esmo.org/ ESMO]== | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
| − | *[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://www.ncbi.nlm.nih.gov/pubmed/25210080 PubMed] | + | ==[https://www.esmo.org/ ESMO]== |
| | + | *[https://www.sciencedirect.com/science/article/pii/S0923753419340876?via%3Dihub Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080/ PubMed] |
| | | | |
| | ==NCCN== | | ==NCCN== |
| − | *[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma] | + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma] |
| − | | |
| − | =Angiosarcoma, all lines of therapy=
| |
| − | | |
| − | ==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − | | |
| − | ===Regimen {{#subobject:c663b6|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |-
| |
| − | |[http://annonc.oxfordjournals.org/content/24/1/257.long Agulnik et al. 2013]
| |
| − | |style="background-color:#EEEE00"|Phase II
| |
| − | |-
| |
| − | |}
| |
| − | ====Chemotherapy====
| |
| − | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
| |
| − | | |
| − | '''21-day cycles, given until progression of disease, intolerance, unacceptable toxicity, patient refusal, or physician discretion'''
| |
| − | | |
| − | ===References===
| |
| − | # Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [http://annonc.oxfordjournals.org/content/24/1/257.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22910841 PubMed]
| |
| − | | |
| − | ==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − | ===Regimen {{#subobject:ebf64d|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |-
| |
| − | |[http://jco.ascopubs.org/content/26/32/5269.long Penel et al. 2008 (ANGIOTAX)]
| |
| − | |style="background-color:#EEEE00"|Phase II
| |
| − | |-
| |
| − | |}
| |
| − | ====Chemotherapy====
| |
| − | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
| |
| − | | |
| − | ====Supportive medications====
| |
| − | *[[Dexamethasone (Decadron)]] 8 mg IV once prior to paclitaxel
| |
| − | *[[Cimetidine (Tagamet)]] 200 mg IV once prior to paclitaxel
| |
| − | *[[Dexchlorpheniramine (Polaramine)]] (note: was spelled as dexchloropheramine in the Penel et al. 2008) 5 mg IV once prior to paclitaxel
| |
| − | *"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician"
| |
| − | | |
| − | '''28-day cycle for 6 cycles, given until progression of disease or unacceptable toxicity'''
| |
| − | | |
| − | ===References===
| |
| − | # Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [http://jco.ascopubs.org/content/26/32/5269.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18809609 PubMed]
| |
| − | | |
| | =Hemangioendothelioma, all lines of therapy= | | =Hemangioendothelioma, all lines of therapy= |
| − |
| |
| | =Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | | =Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= |
| − |
| |
| − | =Kaposi sarcoma, all lines of therapy=
| |
| − |
| |
| − | ==ABV {{#subobject:4531b5|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − | ABV: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine
| |
| − |
| |
| − | ===Regimen #1 {{#subobject:d923d9|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |'''Comparator'''
| |
| − | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
| |
| − | |-
| |
| − | |[http://jco.ascopubs.org/content/16/7/2445.long Northfelt et al. 1998]
| |
| − | |style="background-color:#00CD00"|Phase III
| |
| − | |[[Soft tissue sarcoma#Doxorubicin_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
| |
| − | |style="background-color:#d73027"|Inferior ORR
| |
| − | |-
| |
| − | |}
| |
| − | ====Chemotherapy====
| |
| − | *[[Doxorubicin (Adriamycin)]] 20 mg/m<sup>2</sup> IV once on day 1
| |
| − | *[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once on day 1
| |
| − | *[[Vincristine (Oncovin)]] 1 mg IV once on day 1
| |
| − |
| |
| − | ====Supportive medications====
| |
| − | *"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators."
| |
| − |
| |
| − | '''14-day cycle for up to 6 cycles'''
| |
| − |
| |
| − | ===Regimen #2 {{#subobject:b47ecf|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |'''Comparator'''
| |
| − | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
| |
| − | |-
| |
| − | |[http://jco.ascopubs.org/content/14/8/2353.long Gill et al. 1996]
| |
| − | |style="background-color:#00CD00"|Phase III
| |
| − | |[[Soft tissue sarcoma#Daunorubicin_liposomal_monotherapy|Liposomal daunorubicin]]
| |
| − | |style="background-color:#ffffbf"|Seems not superior
| |
| − | |-
| |
| − | |}
| |
| − |
| |
| − | ''Gill et al. 1996 described doses but did not clearly say in the paper when these drugs were given, but this schedule is assumed based on the Northfelt et al. 1998 ABV regimen.''
| |
| − | ====Chemotherapy====
| |
| − | *[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup> IV once on day 1
| |
| − | *[[Bleomycin (Blenoxane)]] 15 units IV once on day 1
| |
| − | *[[Vincristine (Oncovin)]] 1 mg IV once on day 1
| |
| − |
| |
| − | ====Supportive medications====
| |
| − | *"No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator"
| |
| − |
| |
| − | '''14-day cycle for minimum of 2 cycles; given until complete remission, unacceptable toxicity, disease progression, patient refusal, or death'''
| |
| − |
| |
| − | ===References===
| |
| − | # Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M,Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. [http://jco.ascopubs.org/content/14/8/2353.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8708728 PubMed]
| |
| − | # Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. [http://jco.ascopubs.org/content/16/7/2445.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667262 PubMed]
| |
| − |
| |
| − | ==Bevacizumab monotherapy {{#subobject:25316e|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − | ===Regimen {{#subobject:48507a|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |-
| |
| − | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383119/ Uldrick et al. 2012]
| |
| − | |style="background-color:#EEEE00"|Phase II
| |
| − | |-
| |
| − | |}
| |
| − |
| |
| − | ====Loading dose====
| |
| − | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once as a loading dose; start regular therapy 7 days later after this loading dose
| |
| − |
| |
| − | ====Regular therapy====
| |
| − | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1
| |
| − |
| |
| − | ====Supportive medications====
| |
| − | *"Antihypertensive therapy was initiated for systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg persisting for more than 1 week or for systolic blood pressure greater than 210 mmHg or diastolic blood pressure greater than 120 mmHg at any time."
| |
| − | *"HIV-positive patients with CD4 count of less than 200 cells/µL received Pneumocystis jiroveci prophylaxis."
| |
| − | *"Mycobacterium avium prophylaxis was considered if CD4 count was less than 75 cells/µL."
| |
| − | *Patients with HIV/AIDS continued HAART
| |
| − | *[[Filgrastim (Neupogen)]] "used as clinically indicated"
| |
| − |
| |
| − | '''21-day cycles, given until progression of disease requiring cytotoxic therapy, lack of adherence to protocol (including HAART), or patient-requested discontinuation'''
| |
| − |
| |
| − | ===References===
| |
| − | # Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012 May 1;30(13):1476-83. Epub 2012 Mar 19. [http://jco.ascopubs.org/content/30/13/1476.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383119/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22430271 PubMed]
| |
| − |
| |
| − | ==Daunorubicin liposomal monotherapy {{#subobject:92db30|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − | ===Regimen {{#subobject:95ce2a|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |'''Comparator'''
| |
| − | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
| |
| − | |-
| |
| − | |[http://jco.ascopubs.org/content/14/8/2353.long Gill et al. 1996]
| |
| − | |style="background-color:#00CD00"|Phase III
| |
| − | |[[Soft tissue sarcoma#ABV|ABV]]
| |
| − | |style="background-color:#ffffbf"|Seems not superior
| |
| − | |-
| |
| − | |}
| |
| − | ====Chemotherapy====
| |
| − | *[[Daunorubicin liposomal (DaunoXome)]] 40 mg/m<sup>2</sup> IV over 30 to 60 minutes once on day 1
| |
| − |
| |
| − | ====Supportive medications====
| |
| − | *"No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator"
| |
| − |
| |
| − | '''14-day cycle for minimum of 2 cycles; given until complete remission, unacceptable toxicity, disease progression, patient refusal, or death'''
| |
| − |
| |
| − | ===References===
| |
| − | # Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M,Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. [http://jco.ascopubs.org/content/14/8/2353.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8708728 PubMed]
| |
| − |
| |
| − | ==Doxorubicin liposomal monotherapy {{#subobject:a880c2|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − |
| |
| − | ===Regimen {{#subobject:6a33ec|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |'''Comparator'''
| |
| − | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']]
| |
| − | |-
| |
| − | |[http://jco.ascopubs.org/content/16/7/2445.long Northfelt et al. 1998]
| |
| − | |style="background-color:#00CD00"|Phase III
| |
| − | |[[Soft tissue sarcoma#ABV|ABV]]
| |
| − | |style="background-color:#1a9850"|Superior ORR
| |
| − | |-
| |
| − | |}
| |
| − | ====Chemotherapy====
| |
| − | *[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV over 30 minutes once on day 1
| |
| − |
| |
| − | ====Supportive medications====
| |
| − | *"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators."
| |
| − |
| |
| − | '''14-day cycle for up to 6 cycles'''
| |
| − |
| |
| − | ===References===
| |
| − | # Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. [http://jco.ascopubs.org/content/16/7/2445.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667262 PubMed]
| |
| − |
| |
| − | ==Etoposide monotherapy {{#subobject:9b5ac9|Regimen=1}}==
| |
| − | {| class="wikitable" style="float:right; margin-left: 5px;"
| |
| − | |-
| |
| − | |[[#top|back to top]]
| |
| − | |}
| |
| − | ===Regimen {{#subobject:a25060|Variant=1}}===
| |
| − | {| border="1" style="text-align:center;" !align="left"
| |
| − | |'''Study'''
| |
| − | |[[Levels_of_Evidence#Evidence|'''Evidence''']]
| |
| − | |-
| |
| − | |[http://jco.ascopubs.org/content/20/15/3236.long Evans et al. 2002]
| |
| − | |style="background-color:#EEEE00"|Phase II
| |
| − | |-
| |
| − | |}
| |
| − | ====Chemotherapy====
| |
| − | *[[Etoposide (Vepesid)]] 50 mg PO once per day on days 1 to 7
| |
| − |
| |
| − | '''14-day cycles'''
| |
| − |
| |
| − | ===References===
| |
| − | # Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002 Aug 1;20(15):3236-41. [http://jco.ascopubs.org/content/20/15/3236.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12149296 PubMed]
| |
| − |
| |
| | [[Category:Vascular sarcoma regimens]] | | [[Category:Vascular sarcoma regimens]] |
| | [[Category:Disease-specific pages]] | | [[Category:Disease-specific pages]] |
| | [[Category:Soft tissue sarcomas]] | | [[Category:Soft tissue sarcomas]] |
